Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,788 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MAJOR DEPRESSIVE DISORDER Clear all
Withdrawn Not applicable Interventional

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD), Withdrawn

NCT03769350
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Smartphone-delivered CBT for MDD
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

PET Biomarkers in Treatment Resistant Depression

NCT01031810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders

NCT02860910
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Menopause
Interventions
Cognitive Behavioral Group Therapy
Behavioral
Lead sponsor
Danette Conklin, PhD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Cognitive Training for Depression II

NCT01934491
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Training A, Cognitive Training B
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 15, 2026, 5:59 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors

NCT01652768
View directory record Official record
Conditions
Malignant Brain Tumors
Interventions
Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers, Contact every 2 weeks, Follow-up Surgical Visit Session, Medical and/or Radiation Oncology Appointment Session
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

NCT02594696
View directory record Official record
Conditions
Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions
Proactive Psychiatry Consultation (PPC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Imaging Depression in Parkinson's Disease

NCT06402955
View directory record Official record
Conditions
Parkinson's Disease, Major Depressive Disorder
Interventions
11C-UCB-J, ketamine hydrochloride
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

NCT01957410
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Defining Neurobiological Links Between Substance Use and Mental Illness

NCT05538910
View directory record Official record
Conditions
Major Depressive Disorder, Substance Use Disorder, Normal Physiology
Interventions
Placebo Nicotine Patch, Nicotine Patch
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neutralizing Interleukin (IL)-6

NCT07493317
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression

NCT04469322
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major, Depression, Bipolar, Depressive Episode
Interventions
Mental Health DNA Insight Test (Pathway Genomics), Sham Test
Diagnostic Test
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia

NCT06493825
View directory record Official record
Conditions
Tinnitus, Misophonia
Interventions
Aurora Mindfulness app versus sham
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

NCT01507155
View directory record Official record
Conditions
Treatment Resistant Depression, Generalized Anxiety Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chalfont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

NCT05016050
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
HPDT-DA-013
Device
Lead sponsor
Happify Inc.
Industry
Eligibility
22 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Results available

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

NCT00401726
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Venlafaxine ER, Dialogues Time to Talk Program
Drug · Behavioral
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 4 Interventional Results available

Neurobiological Bases of Placebo Response in Major Depressive Disorder

NCT01787240
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Augmented Human Intelligence in Major Depressive Disorder

NCT04355650
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Clinical decision support tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional

tDCS: Sleep to Mood in Depression (S2M-D)

NCT07572526
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression, Major Depressive Episode
Interventions
transcranial direct current stimulation (tDCS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07065240
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300, Placebo
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Chino, California • Garden Grove, California • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 15, 2026, 5:59 PM EDT